GLP-3 RT
A triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Reported in published Phase 3 research literature on adiposity and metabolic endpoints.
Half-life
~6 days
Typical vial
10 mg
Mechanism
Co-activation of GLP-1, GIP, and glucagon receptors is studied for combined effects on satiety, insulin response, and energy expenditure.
Research Applications
- Adiposity models
- Glycemic regulation
- Energy expenditure
Handling & Storage
Store lyophilized at -20°C. Reconstitute with water and refrigerate.
Compliance notice: All materials are sold strictly for in vitro laboratory research. Not a drug, supplement, food, or cosmetic. Not for human or veterinary use, diagnosis, treatment, or consumption. No medical claims are made or implied. Buyers must be qualified researchers ≥21 years of age and agree to handle materials in compliance with all applicable local, state, and federal laws.